NCT06385184

Brief Summary

Adults with Parkinson's Disease experience an array of challenges and changes in daily living, behaviors, and functioning throughout the progression of their condition. The investigators want to learn more about the effects of Parkinson's Disease on individuals' social behavior and quality of life (QoL) compared to people of the same age without Parkinson's Disease.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
19mo left

Started Mar 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress58%
Mar 2024Dec 2027

Study Start

First participant enrolled

March 8, 2024

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 18, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 25, 2024

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

February 13, 2026

Status Verified

February 1, 2026

Enrollment Period

3.8 years

First QC Date

April 18, 2024

Last Update Submit

February 11, 2026

Conditions

Outcome Measures

Primary Outcomes (5)

  • Subjective Quality of Life

    satisfaction with different aspects of life, such as health and social relationships

    through study completion, an average of 1 year

  • Social Behavior

    ability to interact with others

    through study completion, an average of 1 year

  • Activities of Daily Living

    ability to complete tasks to be independent

    through study completion, an average of 1 year

  • Mental Health

    depression and anxiety symptoms

    through study completion, an average of 1 year

  • Cognition

    memory and executive function challenges and strengths

    through study completion, an average of 1 year

Study Arms (2)

Parkinson's disease

This group includes adults who: * Have been diagnosed with Parkinsons Disease by a healthcare professional * Are at least 40 years old and * Do not possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome)

Other: No Intervention

Neurotypical adults

This group includes adults who: * Are at least 40 years old * Do not have a diagnosis of Parkinsons Disease or any form of dementia and * Do not have a diagnosis of autism or any other developmental disability (e.g., Down syndrome)

Other: No Intervention

Interventions

Observational study with no intervention

Neurotypical adultsParkinson's disease

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study includes both 40+ year old adults with Parkinson's disease and 40+ year old neurotypical adults

You may qualify if:

  • Have been diagnosed with Parkinsons Disease by a healthcare professional
  • Are at least 40 years old

You may not qualify if:

  • Possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome)
  • Neurotypical group
  • Are at least 40 years old
  • Have been diagnosed with Parkinson's disease by a healthcare professional
  • Possess a diagnosis of autism or any other developmental disability (e.g., Down syndrome)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The George Washington University

Washington D.C., District of Columbia, 20052, United States

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

  • Gregory Wallace, PhD

    George Washington University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gregory Wallace, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
PI

Study Record Dates

First Submitted

April 18, 2024

First Posted

April 25, 2024

Study Start

March 8, 2024

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

February 13, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Currently, there is no plan to share participant data with other researchers.

Locations